Predictors of Sexual Dysfunction in Women Seeking Treatment for Opioid Use Disorder: A Comparative Cross-Sectional Study from a Tertiary Center

Creative Commons License

Saglam N. G. U., Ergelen M., Kilic M. K., Bestepe E. E., BİLİCİ R.

Haseki Tip Bulteni, cilt.61, sa.5, ss.358-365, 2023 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 61 Sayı: 5
  • Basım Tarihi: 2023
  • Doi Numarası: 10.4274/haseki.galenos.2023.9493
  • Dergi Adı: Haseki Tip Bulteni
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.358-365
  • Anahtar Kelimeler: buprenorphine/naloxone drug combination, depression, female, Opioid use disorder, sexual dysfunction
  • İstanbul Ticaret Üniversitesi Adresli: Evet

Özet

Aim: There is a critical need for scientific evidence on the sexual and reproductive health of women with opioid use disorder (OUD). The main objective of this study was to evaluate sexual dysfunction (SD) and depression in women with OUD and compare them with healthy controls, in addition to exploring possible predictors of SD. Methods: This cross-sectional study was conducted between January and July 2023. Thirty-four women with OUD, according to the DSM-5, and 30 healthy controls were included. The Female Sexual Function Index (FSFI), Patient Health Questionnaire-9 (PHQ-9), and sociodemographic questionnaire were used to evaluate SD, depression, and characteristics related to substance use and sexual/ reproductive history. Logistic regression analysis was performed to determine the predictors of SD in women with OUD. Results: Twenty-nine percent (n=10) of the participants with OUD had SD. The scores of the FSFI desire, arousal, lubrication, orgasm (p=0.001 for all), satisfaction (p=0.001) subscales, and the total score (p<0.001) were lower in women with OUD than in the controls. Daily dosage of buprenorphine/naloxone [Odds ratio (OR)=1,956, p=0.027, 95% confidence interval (CI)=1,079-3,545] and PHQ-9 score (OR=1,403, p=0.012, 95% CI=1,076-1,829) were significantly associated with SD in women with OUD. Conclusion: The high prevalence of SDs highlights the unmet sexual health needs of women with OUD. Screening and addressing depressive symptoms should be one of the first steps when caring for SDs in women with OUD.